2020 Q3 BQ Journal Vol 40 - 27

Morbidity and Mortality Weekly Report

References

the use of compact, prefilled autodisable devices; integration
of reproductive, maternal, newborn, and child health services
with vaccination services to optimize maternal immunization; and integration of TTCV SIAs with other SIAs, such as
serogroup A meningococcal vaccine (MenA), measles-rubella,
yellow fever, and polio campaigns. Efforts to strengthen NT
surveillance through community engagement could serve as a
platform for creating community-based surveillance systems
for other diseases, and case-based surveillance for NT could be
integrated with polio and measles case-based surveillance.§§§§
§§§§

1. United Nations Children's Fund, World Health Organization, United
Nations Population Fund. Maternal and neonatal tetanus elimination by
2005: strategies for achieving and maintaining elimination. New York,
NY: United Nations Children's Fund; Geneva, Switzerland: World Health
Organization; New York, NY: United Nations Population Fund; 2000.
https://www.unicef.org/french/health/files/MNTE_strategy_paper.pdf
2. World Health Organization. Protecting all against tetanus: guide to
sustaining maternal and neonatal tetanus elimination and broadening
tetanus protection for all populations. Geneva, Switzerland: World
Health Organization; 2019. https://apps.who.int/iris/bitstream/hand
le/10665/329882/9789241515610-eng.pdf?ua=1
3. World Health Organization, United Nations Children's Fund.
Immunization, vaccines and biologicals: data, statistics and graphics.
Geneva, Switzerland: World Health Organization; New York, NY: United
Nations Children's Fund; 2019. https://www.who.int/immunization/
monitoring_surveillance/data/en/
4. World Health Organization. Immunization, vaccines and biologicals:
maternal and neonatal tetanus elimination. Geneva, Switzerland: World
Health Organization; 2019 http://www10.who.int/immunization/
diseases/MNTE_initiative/en/index7.html
5. Khan R, Vandelaer J, Yakubu A, Raza AA, Zulu F. Maternal and neonatal
tetanus elimination: from protecting women and newborns to protecting
all. Int J Womens Health 2015;7:171-80.
6. Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet
2007;370:1947-59 https://doi.org/10.1016/S0140-6736(07)61261-6
7. United Nations Children's Fund (UNICEF), World Health Organization
(WHO). UNICEF/WHO joint database: delivery at care. New York,
NY: UNICEF; 2019. https://data.unicef.org/topic/maternal-health/
delivery-care/
8. World Health Organization. Validation of maternal and neonatal tetanus
elimination. Geneva, Switzerland: World Health Organization; 2014.
https://www.who.int/immunization/documents/MNTE_Validation_
survey_WHO_IVB_18.15.pdf
9. World Health Organization. Maternal and neonatal tetanus elimination
(MNTE): validating MNT elimination. Geneva, Switzerland: World
Health Organization; 2020. https://www.who.int/immunization/
diseases/MNTE_initiative/en/index2.html
10. World Health Organization. Protection-at-birth method, Tunisia:
monitoring tetanus toxoid coverage and avoiding missed opportunities
for tetanus toxoid vaccination. Wkly Epidemiol Rec 2000;75:203-6.

https://www.who.int/immunization/monitoring_surveillance/burden/vpd/
WHO_SurveillanceVaccinePreventable_14_NeonatalTetanus_R1.pdf.

Acknowledgment
United Nations Children's Fund (UNICEF) country offices in
Yemen, Nigeria, Pakistan, South Sudan, Guinea; UNICEF regional
officers: Mehoundo Faton, West and Central Africa Regional
Office; Daniel Ngemera, Middle East and North Africa Regional
Office. World Health Organization offices in the 45 MNT-validated
countries and their regional offices counterparts.
Corresponding author: Henry N. Njuguna, vkc7@cdc.gov, 404-718-3535.
1 Global Immunization Division, Center for Global Health, CDC;
2Immunization, Vaccines and Biologicals, World Health Organization, Geneva,
Switzerland; 3Maternal, Newborn, and Adolescent Health Program Division,

UNICEF, New York, New York.

All authors have completed and submitted the International
Committee of Medical Journal Editors form for disclosure of potential
conflicts of interest. No potential conflicts of interest were disclosed.

520

MMWR / May 1, 2020 / Vol. 69 / No. 17

US Department of Health and Human Services/Centers for Disease Control and Prevention

Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
27

20MS5677_BQ_journal_40.indd 27

A Henry Schein Publication

7/13/20 12:19 PM

2020 Q3 BQ Journal Vol 40

Table of Contents for the Digital Edition of 2020 Q3 BQ Journal Vol 40